Synlogic Links Up With AbbVie For IBD Microbiome Therapies

Synlogic Inc., focused on the intersection of synthetic biology and microbiome therapeutics, signed its first partnership Feb. 10, agreeing to a multi-year collaboration with AbbVie Inc. to develop what it calls "synthetic biotic" therapies for Crohn's disease and ulcerative colitis.